| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/30/2013 | EP2550968A1 Non-surgical removal of localized fat accumulation with a bile salt in conjunction with an analgesic or anti-inflammatory agent |
| 01/30/2013 | EP2550014A1 Papillomavirus virus-like particle or capsomere formulation and its use as microbicide |
| 01/30/2013 | EP2550004A1 Heparan sulfate replacement therapy |
| 01/30/2013 | CN102905728A Nanocarrier compositions with uncoupled adjuvant |
| 01/30/2013 | CN102905709A Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
| 01/30/2013 | CN102905698A Combination therapy comprising CCR5 antagonist, HIV-1 protease inhibitor and pharmacokinetic enhancer |
| 01/30/2013 | CN102895667A Method for preparing lactobionic acid-crosslinked hepatic cell targeted viral vector |
| 01/30/2013 | CN102895665A Preparation method of targeting graphene nano-grade drug carrier |
| 01/30/2013 | CN102895663A Compositions containing EGFL 7 antagonist for modulating vascular development and methods |
| 01/30/2013 | CN102895662A Composition for chemoembolotherapy of solid tumors |
| 01/30/2013 | CN102895661A Application of medicine targeting CysLT1 in preparing medicines for preventing or treating autoimmune diseases |
| 01/30/2013 | CN102895230A Antituberculous composition comprising oxazole compounds |
| 01/30/2013 | CN102895196A Method for preparing microspheres through oil in nano-particle suspension-oil in oil-solid in oil |
| 01/30/2013 | CN102302455B Method for preparing microsphere preparation coated with hydrophilic medicaments |
| 01/30/2013 | CN102196819B Composition for local anesthesia |
| 01/30/2013 | CN101553256B Phenylpropionamide compounds and the use thereof |
| 01/30/2013 | CN101258166B Antibody combining with STEAP-1 protein and deriving molecule thereof |
| 01/29/2013 | US8362264 Compositions and methods for the treatment of disease associated with Trp-p8 expression |
| 01/29/2013 | US8362231 RNA interference mediating small RNA molecules |
| 01/29/2013 | US8362078 Method for reducing the severity of neurological disorders |
| 01/29/2013 | US8362058 Bicyclic compound, production and use thereof |
| 01/29/2013 | US8361986 Synthetic agonists of TLR9 |
| 01/29/2013 | US8361981 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| 01/29/2013 | US8361512 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 01/29/2013 | US8361497 Multi-phase, multi-compartment, capsular delivery apparatus and methods for using the same |
| 01/29/2013 | US8361485 Conditioned cell culture medium compositions and methods of use |
| 01/29/2013 | US8361483 Epinecidin-1 as a vaccine adjuvant for enhancing immune responses |
| 01/29/2013 | US8361478 Recombinant viral-based malaria vaccines |
| 01/29/2013 | US8361476 With a carrier peptide adjuvant that is able to strongly enhance the immune response to a specific co-administered antigen |
| 01/29/2013 | US8361466 Tweak receptor |
| 01/29/2013 | US8361452 For oral administration, comprising polyethylene glycol, dibasic sodium phosphate; and, optionally, monobasic sodium phosphate; taken dissolved in water, for pre-surgery, constipation; improved patient compliance |
| 01/29/2013 | US8361444 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 01/29/2013 | CA2525946C Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 01/29/2013 | CA2460000C Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 01/29/2013 | CA2459822C Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 01/29/2013 | CA2431891C Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 01/29/2013 | CA2416137C Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 01/29/2013 | CA2343929C Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 01/24/2013 | US20130023688 Phosphorus-containing compounds with polymeric chains, and methods of making and using the same |
| 01/24/2013 | US20130023503 Nk1 antagonists |
| 01/24/2013 | US20130023470 Exendin and exendin agonists for eating disorders |
| 01/24/2013 | US20130023466 Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders |
| 01/23/2013 | EP2548888A1 Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same |
| 01/23/2013 | EP2548580A1 Pharmaceutical for pseudo-exercise therapy |
| 01/23/2013 | EP2547765A1 Beta-propiolactone for inactivation of viruses in pharmaceutical pancreatic enzyme preparations |
| 01/23/2013 | EP2547349A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 01/23/2013 | EP2547326A1 Synergistic preservative compositions |
| 01/23/2013 | CN1606545B Pyrrolidine and piperidine derivates as nk1 antagonists |
| 01/23/2013 | CN102892433A Staining composition |
| 01/23/2013 | CN102892418A Nicotine-containing pharmaceutical compositions |
| 01/23/2013 | CN102886046A Preparation method of fat-soluble chemotherapeutic medicament loaded on calcium phosphate nano carrier and application of fat-soluble chemotherapeutic medicament in preparation of antitumor medicaments |
| 01/23/2013 | CN102886045A Method for treating gefitinib resistant cancer |
| 01/23/2013 | CN102885854A Taiwanese green propolis extractants used for the purpose of slowing down progression of disease of patient |
| 01/23/2013 | CN102885784A Method for preparing microspheres by using oil-in-nanoparticle mixed suspension-nanometer medicament-in-oil |
| 01/23/2013 | CN102885783A Nanometer medicament microspheres |
| 01/23/2013 | CN101507717B Composite tablet capable of treating peptic ulcer and preparation method thereof |
| 01/23/2013 | CN101485629B Drug delivery system and preparation method thereof |
| 01/22/2013 | US8357670 Oligomeric compounds for the modulation of HIF-1A expression |
| 01/22/2013 | US8357400 Stimuli-responsive systems for controlled drug delivery |
| 01/22/2013 | US8357399 Tamper-resistant oral opioid agonist formulations |
| 01/22/2013 | US8357377 Drug carriers; such as nucleic acids; sustained release; biocompatibility polymer |
| 01/22/2013 | US8357374 Conjugates of synthetic TLR agonists and uses therefor |
| 01/22/2013 | US8357372 Agent for treating allergic or hypersensitivity condition |
| 01/22/2013 | CA2483525C Method of measuring neprilysin activity |
| 01/22/2013 | CA2441970C Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 01/22/2013 | CA2402402C Use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treating adverse effects of anti-parkinsonian drugs |
| 01/22/2013 | CA2329267C A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upflp, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 01/17/2013 | WO2013007698A1 Pharmaceutical composition for neurological disorders |
| 01/17/2013 | WO2013007660A1 Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| 01/17/2013 | WO2012135095A3 S1p antagonists as adjunct ocular hypotensives |
| 01/17/2013 | WO2012068234A3 Antiviral compounds |
| 01/17/2013 | WO2011157908A8 Use of the combination of an inhibitor of the if current of the sinoatrial node and an inhibitor of the angiotensin-converting enzyme for treating heart failure |
| 01/17/2013 | US20130018431 Method for directed intranasal administration of a composition |
| 01/17/2013 | US20130018089 Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
| 01/17/2013 | US20130017263 Gastric acid secretion inhibiting composition |
| 01/17/2013 | US20130017244 Sustained release intraocular implants and related methods |
| 01/17/2013 | US20130017172 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus |
| 01/17/2013 | CA2841238A1 Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| 01/16/2013 | EP2546269A1 Monoclonal antibody against necrosis marker prdx4 and use thereof |
| 01/16/2013 | EP2546266A1 MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERp29 AND USE THEREOF |
| 01/16/2013 | EP2546234A1 Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient |
| 01/16/2013 | EP2545939A2 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| 01/16/2013 | EP2545931A1 Herbal therapy for the treatment of food allergy |
| 01/16/2013 | EP2545915A1 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain |
| 01/16/2013 | EP2545914A1 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain |
| 01/16/2013 | EP2545170A1 Death associated protein 1 variants and use thereof for modulating autophagy |
| 01/16/2013 | EP2544696A1 Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders |
| 01/16/2013 | EP2544690A2 Arylvinylazacycloalkane compounds for constipation |
| 01/16/2013 | EP2544686A2 Combination methods for treatment of disease |
| 01/16/2013 | EP2544680A2 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 01/16/2013 | CN102875647A Ligand polypeptide and medicine transferring system combined with specificity of CD40L protein |
| 01/16/2013 | CN102872461A Combination therapy for the treatment of hcv infection |
| 01/16/2013 | CN102871996A Antibiotic composition and application thereof |
| 01/16/2013 | CN102871953A Super-absorbent adsorption suppository |
| 01/16/2013 | CN102251317B Preparation method of electrospun fibers with controllable drug release |
| 01/16/2013 | CN101969961B Combined use of cholestanol derivative |
| 01/16/2013 | CN101912611B Drug composition with anti-tumor effect |
| 01/16/2013 | CN101480376B Method of preparing particles for agglomeration |
| 01/15/2013 | US8354448 Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes |
| 01/15/2013 | US8354409 Combination of brimonidine and timolol for topical ophthalmic use |